MCM
CAI

MAI Capital Management’s Caris Life Sciences CAI Stock Holding History

MAI Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,035
Closed -$18.5K – 5022
2026
Q1 		$18.5K Buy
1,035
+35
+4% +$765 ﹤0.01% 2840
2025
Q4 		$27K Buy
+1,000
New +$28.2K ﹤0.01% 2360

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

MAI Capital Management's CAI Position: Q2 2026 in Review

MAI Capital Management sold out of Caris Life Sciences (CAI) in Q2 2026, closing a stake of 1,035 shares — an estimated $18.5K sold.

MAI Capital Management first reported a position in CAI in Q4 2025 and held it in 2 quarters. The position peaked at $27K in Q4 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • MAI Capital Management reported no remaining Caris Life Sciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,035 Caris Life Sciences shares in Q2 2026, an estimated $18.5K.
  • MAI Capital Management first reported a position in Caris Life Sciences in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Caris Life Sciences position peaked at $27K in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.